article thumbnail

STAT+: Drug shortages reached a record high as 2023 drew to a close

STAT

stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The number of ongoing and active drug shortages in the U.S.

article thumbnail

STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more

STAT

stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunity 103
article thumbnail

What Can One Life Tell Us About the Battle Against H.I.V.?

NY Times

In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. That preceded an ambitious global campaign to curb the virus. How well did it work?

article thumbnail

GSK enters agreement with Canada for influenza vaccines

Pharmaceutical Technology

The latest contract comes after previous agreements between the parties for seasonal influenza and pandemic vaccines dating back to 2001. Arepanrix includes a monovalent, inactivated influenza virus antigen strain as well as the pandemic adjuvant system of GSK.

article thumbnail

PharmaShots Weekly Snapshots (April 03 - 07, 2023)

PharmaShots

TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis Date: Apr 3, 2023 | Tags: TG Therapeutics, Briumvi, Ublituximab-xiiy, Multiple Sclerosis, Regulatory, EMA, CHMP BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for (..)

article thumbnail

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

pharmaphorum

Most CRISPR therapies clinical trials so far have taken the ex vivo approach, but a number of in vivo therapies have now started testing in humans, including Editas’ EDIT-101 for LCA10, a rare form of blindness, and Intellia/Regeneron’s NTLA-2001 transthyretin amyloidosis.